Another study by Zhang et al. (2020) analyzed 310 late-stage non-small cell lung cancer (NSCLC) patients receiving ICI therapies and found that the patients with normal HGB levels (≥110 g/L) had significantly longer OS and PFS than those with lower HGB levels. The gene discussed is CYGB; the disease is non-small cell lung carcinoma.